‘Protalix’ Gets FDA Approval Of Gaucher Disease Drug

The U.S. Food and Drug Administration’s approved for marketing Protalix BioTherapeutics’ drug Elelyso – for the treatment of Type 1 Gaucher disease. The rare genetic disorder occurs in people who do not produce enough of an enzyme called glucocerebrosidase, resulting in liver or spleen damage, anemia, low blood platelet counts and bone problems. The drug is an injection that replaces the missing enzyme in patients with a confirmed diagnosis of Type 1 (non-neuropathic). Following the approval, Protalix will receive a $25 million milestone payment from Pfizer, which developed the treatment with the Israeli company.